Prophylactic Application of an Anti-Cytomegalovirus Hyperimmunoglobulin in Allogeneic Bone Marrow Transplant Recipients

Interstitial pneumonia (IP) is still a life-threatening complication after allogeneic bone marrow transplantation (BMT). It is reported to occur in about 40% of all patients [1]. Almost half the cases of IP are associated with cytomegalovirus (CMV), whereas one-third of IP remains idiopathic. CMV-associated IP has a mortality of up to 90% [1].